Published on 17 Apr 2014
There is much to learn about how a
diverse, robust gastrointestinal microbiota is essential to the health
of our gastrointestinal and immune systems. This presentation will
review the critical role the gut microbiota plays in maintaining health.
Participants will understand that the human intestinal microbiota
functions as an organ and is critical for immune and gastrointestinal
system maturation, colonization resistance, modulation of immune
responses, and nutritional needs. The use of probiotics and prebiotics
to support a healthful gut microbiota will be covered in practical
details. Probiotics are microorganisms that when consumed provide
numerous health benefits.
A variety of probiotics are available to
health practitioners; most of them are lactic acid bacteria and
bifidobacteria. The disorders in which the beneficial use of probiotics
is documented include antibiotic-associated GI distress, C.
difficile-associated diarrhea, inflammatory bowel disease, irritable
bowel disease, dysbiosis, urinary tract infections, allergies, atopic
dermatitis, eczema, and lactose intolerance. Multispecies probiotics are
generally more effective than single species formulas. Prebiotics
increase the numbers and/or activities of healthful gut microbiota.
Prebiotics are useful to increase Bifidobacterium populations and to
support populations of healthful genera such as Eubacterium and
Rosaburia that are not available as probiotics. Participants will learn
clinically relevant prebiotic and probiotic interventions that are
beneficial for a number of common gastrointestinal and allergic
disorders. This presentation will foster an appreciation of the
intestinal microbiota and provide participants with the knowledge needed
to effectively use prebiotocs and probiotics to enhance health.
Stephen
F. Olmstead, MD, is Chief Science Officer at ProThera, Inc. where he
directs clinical trials of ProThera® and Klaire Labs™ nutraceutical
products. He received his MD from the University of New Mexico in 1979
and completed his Internal Medicine residency at Harvard Medical School,
Massachusetts General Hospital in 1982 and fellowship in Cardiovascular
Diseases at the University of Washington in 1987. Dr. Olmstead served 2
years in the Commissioned Corps of the US Public Health Service and was
stationed primarily at the Indian Health Service Hospital in Gallup New
Mexico. For many years, Dr. Olmstead spent his career as a Clinical
Assistant Professor in Medicine at the University of Washington Medical
School in Seattle. His current research focuses on the use of enzymes
and chelating agents to disrupt pathogenic GI biofilm and pre- and
probiotics to restore gut microbial balance.
diverse, robust gastrointestinal microbiota is essential to the health
of our gastrointestinal and immune systems. This presentation will
review the critical role the gut microbiota plays in maintaining health.
Participants will understand that the human intestinal microbiota
functions as an organ and is critical for immune and gastrointestinal
system maturation, colonization resistance, modulation of immune
responses, and nutritional needs. The use of probiotics and prebiotics
to support a healthful gut microbiota will be covered in practical
details. Probiotics are microorganisms that when consumed provide
numerous health benefits.
A variety of probiotics are available to
health practitioners; most of them are lactic acid bacteria and
bifidobacteria. The disorders in which the beneficial use of probiotics
is documented include antibiotic-associated GI distress, C.
difficile-associated diarrhea, inflammatory bowel disease, irritable
bowel disease, dysbiosis, urinary tract infections, allergies, atopic
dermatitis, eczema, and lactose intolerance. Multispecies probiotics are
generally more effective than single species formulas. Prebiotics
increase the numbers and/or activities of healthful gut microbiota.
Prebiotics are useful to increase Bifidobacterium populations and to
support populations of healthful genera such as Eubacterium and
Rosaburia that are not available as probiotics. Participants will learn
clinically relevant prebiotic and probiotic interventions that are
beneficial for a number of common gastrointestinal and allergic
disorders. This presentation will foster an appreciation of the
intestinal microbiota and provide participants with the knowledge needed
to effectively use prebiotocs and probiotics to enhance health.
Stephen
F. Olmstead, MD, is Chief Science Officer at ProThera, Inc. where he
directs clinical trials of ProThera® and Klaire Labs™ nutraceutical
products. He received his MD from the University of New Mexico in 1979
and completed his Internal Medicine residency at Harvard Medical School,
Massachusetts General Hospital in 1982 and fellowship in Cardiovascular
Diseases at the University of Washington in 1987. Dr. Olmstead served 2
years in the Commissioned Corps of the US Public Health Service and was
stationed primarily at the Indian Health Service Hospital in Gallup New
Mexico. For many years, Dr. Olmstead spent his career as a Clinical
Assistant Professor in Medicine at the University of Washington Medical
School in Seattle. His current research focuses on the use of enzymes
and chelating agents to disrupt pathogenic GI biofilm and pre- and
probiotics to restore gut microbial balance.
